Last reviewed · How we verify
Acetacin (ACEPROMAZINE)
Acepromazine, marketed under the name Acetacin, is a neuroleptic agent currently on the market, with a key composition patent expiring in 2028. Its unique mechanism of action, binding to the major prion protein, sets it apart from other same-class drugs such as chlorpromazine, levomepromazine, promazine, and triflupromazine. The primary risk is the competitive landscape, particularly from off-patent drugs like promazine, which may limit Acepromazine's market share and revenue potential.
At a glance
| Generic name | ACEPROMAZINE |
|---|---|
| Drug class | acepromazine |
| Target | Major prion protein, D(1A) dopamine receptor, D(2) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines (PHASE1)
- SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma (PHASE2)
- SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetacin CI brief — competitive landscape report
- Acetacin updates RSS · CI watch RSS